Serum immunoglobulin G subclass levels and estimated clinical severity caused by possible influenza A (H1N1) pdm 2009 infection

Journal of Infection and Chemotherapy

Volumn 19, Issue 5, 2013, Pages 833-842

  Yamamoto, Takehisa ^a   Mizoguchi, Yoshimi ^a   Kaneno, Hiroshi ^a   Yamamoto, Katsusuke ^a   Inoue, Yutaka ^a   Kawashima, Hisashi ^b   Kase, Tetsuo ^c   Shimotsuji, Tsunesuke ^a  

^a Minoh City Hospital   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

^c OSAKA PREFECTURAL INSTITUTE OF PUBLIC HEALTH   (Japan)

Author keywords

Estimated clinical severity; H1N1 pdm 2009; IgG subclass; Neuraminidase inhibitor therapy; Pneumonia

Indexed keywords

ANTIBIOTIC AGENT; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; CREATININE; HERBACEOUS AGENT; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN M; MAOTO; METHYLPREDNISOLONE; OSELTAMIVIR; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; ZANAMIVIR;

2009 H1N1 INFLUENZA; ANAMNESIS; ARTICLE; ATELECTASIS; BREATHING RATE; BRONCHITIS; CHILD; CHILD CARE; CLINICAL FEATURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOKINE STORM; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FLU LIKE SYNDROME; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OXYGEN SATURATION; PNEUMONIA; PRESCHOOL CHILD; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD;

ANALYSIS OF VARIANCE; CHILD; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; JAPAN; MALE; MODELS, BIOLOGICAL; SEVERITY OF ILLNESS INDEX;

EID: 84885953060     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-013-0570-4     Document Type: Article

References (33)

1. Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, Hernandez M, Quiñones-Falconi F, Bautista E, et al. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med. 2009;361:680-9.
2. Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza, Bautista E, Chotpitayasunondh T, Gao Z, Harper SA, Shaw M, et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med. 2010;362:1708-19.
3. Jain S, Kamimoto L, Bramley AM, Schmitz AM, Benoit SR, Louie J, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med. 2009;361:1935-44.
4. Maines TR, Belser JA, Gustin KM, van Hoeven N, Zeng H, Svitek N, et al. Local innate immune responses and influenza virus transmission and virulence in ferrets. J Infect Dis. 2012;205:474-85.
5. Palladino G, Mozdzanowska K, Washko G, Gerhard W. Virus-neutralizing antibodies of immunoglobulin G (IgG) but not of IgM or IgA isotypes can cure influenza virus pneumonia in SCID mice. J Virol. 1995;69:2075-81.
6. Renegar KB, Small PA Jr, Boykins LG, Wright PF. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J Immunol. 2004;173:1978-86.
7. Gordon CL, Johnson PD, Permezel M, Holmes NE, Gutteridge G, McDonald CF, et al. Association between severe pandemic 2009 influenza A (H1N1) virus infection and immunoglobulin G(2) subclass deficiency. Clin Infect Dis. 2010;50:672-8.
8. Chan JF, To KK, Tse H, Lau CC, Li IW, Hung IF, et al. The low serum immunoglobulin G2 levels in severe cases than in mild cases of pandemic H1N1 2009 influenza is associated with cytokine dysregulation. Clin Vaccine Immunol. 2011;18:305-10.
9. Zheng R, Qin X, Li Y, Yu X, Wang J, Tan M, et al. Imbalanced anti-H1N1 immunoglobulin subclasses and dysregulated cytokines in hospitalized pregnant women with 2009 H1N1 influenza and pneumonia in Shenyang, China. Hum Immunol. 2012;73:906-11.
10. Bentler PM, Stein JA. Structural equation models in medical research. Stat Methods Med Res. 1992;1:159-81.
11. Beran TN, Violato C. Structural equation modeling in medical research: a primer. BMC Res Notes. 2010;3:267.
12. Kubo T, Nishimura H. Antipyretic effect of Mao-to, a Japanese herbal medicine, for treatment of type A influenza infection in children. Phytomedicine. 2007;14:96-101.
13. Sakai E, Yamamoto T, Yamamoto K, Mizoguchi Y, Kaneno H, Ihashi M, et al. IgG3 deficiency and severity of 2009 pandemic H1N1 influenza. Pediatr Int. 2012;54:758-61.
14. Nishimaki S, Sato M, An H, Shima Y, Akaike T, Yokoyama U, et al. Comparison of markers for fetal inflammatory response syndrome: fetal blood interleukin-6 and neonatal urinary beta2-microglobulin. J Obstet Gynecol Res. 2009;35:472-6.
15. Bentler PM. Comparative fit indices in structural equation models. Psychol Bull. 1990;107:238-46.
16. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B. 1995;57:289-300.
17. Hayashibara H, Tanimoto K, Nagata I, Harada Y, Shiraki K. Normal levels of IgG subclass in childhood determined by a sensitive ELISA. Acta Paediatr Jpn. 1993;35:113-7.
18. Kosmider B, Messier EM, Janssen WJ, Nahreini P, Wang J, Hartshorn KL et al. Nrf2 protects human alveolar epithelial cells against injury induced by influenza A virus. Respir Res. 2012;13(1):43 (Epub ahead of print).
19. Urashima M, Segawa T, Okazaki M, Kurihara M, Wada Y, Ida H. Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. Am J Clin Nutr. 2010;91:1255-60.
20. Gordon CL, Langan K, Charles PGP, Bellomo R, Hart GK, Torresi J, et al. Pooled human immunoglobulin therapy in critically ill patients with pandemic 2009 influenza A (H1N1) pneumonitis and immunoglobulin G2 subclass (IgG2) deficiency. Clin Infect Dis. 2011;52:422-6.
21. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006;145:599-609.
22. Merrill WW, Naegel GP, Olchowski JJ, Reynolds HY. Immunoglobulin G subclass proteins in serum and lavage fluid of normal subjects. Quantitation and comparison with immunoglobulins A and E. Am Rev Respir Dis. 1985;31:584-7.
23. Hancock K, Veguilla A, Lu X, Zhong W, Butler EN, Sun H, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med. 2009;361:1945-52.
24. Sun Y, Bian C, Xu K, Hu W, Wang T, Cui J, et al. Immune protection induced on day 10 following administration of the 2009 A/H1N1 pandemic influenza vaccine. PLoS ONE. 2010;5:e14270.
25. Halliley JL, Kyu S, Kobie JJ, Walsh EE, Falsey AR, Randall TD, et al. Peak frequencies of circulating human influenza-specific antibody secreting cells correlate with serum antibody response after immunization. Vaccine. 2010;28:3582-7.
26. Siber GR, Schur PH, Aisenberg AC, Weitzman SA, Schiffman G. Correlation between serum IgG-2 concentrations and the antibody response to bacterial polysaccharide antigens. N Engl J Med. 1980;303:178-82.
27. Masiá M, Padilla S, Antequera P, Ramos JM, Ruiz M, Gutiérrez F. Predictors of pneumococcal co-infection for patients with pandemic (H1N1) 2009. Emerg Infect Dis. 2011;17:1475-8.
28. Koon K, Sanders CM, Green J, Malone L, White H, Zayas D, et al. Co-detection of pandemic (H1N1) 2009 virus and other respiratory pathogens. Emerg Infect Dis. 2010;16:1976-8.
29. Lee LN, Dias P, Han D, Yoon S, Shea A, Zakharov V, et al. A mouse model of lethal synergism between influenza virus and Haemophilus influenzae. Am J Pathol. 2010;176:800-11.
30. Pérez de la Lastra JM, Kremer L. Recent advances in the development of immunoadhesins for immune therapy and as anti-infective agents. Recent Pat Antiinfect Drug Discov. 2009;4:183-9.
31. Feng JQ, Mozdzanowska K, Gerhard W. Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype. J Virol. 2002;76:1369-78.
32. Huizinga TW, Kerst M, Nuyens JH, Vlug A, von dem Borne AE, Roos D, et al. Binding characteristics of dimeric IgG subclass complexes to human neutrophils. J Immunol. 1989;142:2359-64.
33. Han K, Ma H, An X, Su Y, Chen J, Lian Z, et al. Early use of glucocorticoids was a risk factor for critical disease and death from pH1N1 infection. Clin Infect Dis. 2011;53:326-33.